CD73 (Cluster of Differentiation 73), also known as Ecto-5'-Nucleotidase (NT5E), is a glycosylphosphatidylinositol (GPI)-anchored cell surface enzyme that catalyzes the hydrolysis of extracellular nucleotides to adenosine. As the rate-limiting enzyme in adenosine production, CD73 plays pivotal roles in purinergic signaling, immune regulation, neuroprotection, and cellular energy balance. This protein is widely expressed in the central nervous system (CNS), where it modulates synaptic transmission, neuroinflammation, and blood-brain barrier (BBB) function.
| Protein Name | CD73 / Ecto-5'-Nucleotidase |
| Gene | NT5E |
| UniProt ID | P21589 |
| PDB ID | 6A75, 4H2O |
| Molecular Weight | 70 kDa (dimer) |
| Subcellular Localization | Cell surface (GPI-anchored), cytoplasm |
| Protein Family | Ecto-nucleotidases, 5'-nucleotidase family |
| Expression | Broad: neurons, astrocytes, microglia, endothelial cells, immune cells |
CD73 is a glycosylphosphatidylinositol (GPI)-anchored enzyme that converts extracellular AMP to adenosine. As the rate-limiting enzyme in adenosine production, CD73 plays critical roles in purinergic signaling, immune regulation, neuroprotection, and synaptic transmission. CD73 hydrolyzes extracellular AMP to adenosine, producing the majority of extracellular adenosine in tissues. This adenosine signals through purinergic receptors (A1, A2A, A2B, A3) to modulate synaptic transmission, neuronal excitability, and glial function. CD73 is essential for astrocyte-neuron metabolic coupling, microglial surveillance, and blood-brain barrier regulation.
CD73 is a homodimeric enzyme with each subunit containing:
| Modification | Site | Functional Impact |
|---|---|---|
| N-glycosylation | Multiple sites | Protein stability, localization |
| GPI anchor | C-terminus | Membrane attachment |
| Disulfide bonds | 8 cysteines | Structural stability |
CD73 is the primary source of extracellular adenosine:
| Receptor | Distribution | Function |
|---|---|---|
| A1 | Wide (hippocampus, cortex) | Inhibitory, neuroprotection |
| A2A | Striatum, immune cells | Pro-inflammatory, motor control |
| A2B | Low basal, induced | Vascular, inflammatory |
| A3 | Variable | Complex, tissue-specific |
| Cell Type | Expression Level | Key Functions |
|---|---|---|
| Astrocytes | High | Metabolic coupling, K⁺ clearance |
| Neurons | Moderate | Synaptic modulation |
| Microglia | Low-Moderate | Immune surveillance |
| Endothelial Cells | High | BBB function |
| Oligodendrocytes | Low | Myelin maintenance |
Following cerebral ischemia:
| Drug/Compound | Target | Status |
|---|---|---|
| CD73 inhibitors | Enzymatic activity | Cancer clinical trials |
| A2A antagonists | A2A receptor | Parkinson's trials |
| A2A agonists | A2A receptor | Neuroprotection |
The study of Nt5E Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.